NCCN Guidelines (R) Insights Head and Neck Cancers, Version 2.2017 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Adelstein, D., Gillison, M. L., Pfister, D. G., Spencer, S., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A., Eisele, D. W., Fenton, M., Foote, R. L., Gilbert, J., Haddad, R. I., Hicks, W. L., Hitchcock, Y. J., Jimeno, A., Leizman, D., Lydiatt, W. M., Maghami, E., Mell, L. K., Mittal, B. B., Pinto, H. A., Ridge, J. A., Rocco, J., Rodriguez, C. P., Shah, J. P., Weber, R. S., Witek, M., Worden, F., Yom, S. S., Zhen, W., Burns, J. L., Darlow, S. D. 2017; 15 (6): 761–70


The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding the increase in human papillomavirus-associated oropharyngeal cancer and the availability of immunotherapy agents for treatment of patients with recurrent or metastatic H&N cancer.

View details for DOI 10.6004/jnccn.2017.0101

View details for Web of Science ID 000403152400004

View details for PubMedID 28596256